Lotus Pharmaceutical Co Ltd Total Assets
Lotus Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Lotus Pharmaceutical Co Ltd (1795) holds total assets worth NT$108.59 Billion TWD (≈ $3.42 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 1795 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Lotus Pharmaceutical Co Ltd (2009–2025)
Total assets of Lotus Pharmaceutical Co Ltd from 2009 to 2025. This chart illustrates how Lotus Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Lotus Pharmaceutical Co Ltd for real-time trading data and today's change.
Lotus Pharmaceutical Co Ltd - Asset Composition Analysis
Lotus Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Lotus Pharmaceutical Co Ltd total assets breakdown as of December 2025. Lotus Pharmaceutical Co Ltd's total assets of NT$108.59 Billion consist of 24.9% current assets and 75.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.3% |
| Accounts Receivable | NT$7.80 Billion | 7.4% |
| Inventory | NT$9.65 Billion | 9.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$25.32 Billion | 23.9% |
| Goodwill | NT$31.95 Billion | 30.1% |
Asset Composition Trend (2009–2025)
This chart illustrates how Lotus Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Lotus Pharmaceutical Co Ltd (1795) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lotus Pharmaceutical Co Ltd's current assets represent 24.9% of total assets in 2025, a decrease from 54.4% in 2009.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 15.6% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 30.1% of total assets.
Lotus Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Lotus Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Lotus Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.46 | 1.55 | 1.92 |
| Quick Ratio | 0.96 | 1.15 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$8.14 Billion | NT$5.34 Billion | NT$3.81 Billion |
Lotus Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Lotus Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.96 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 164.7% |
| Total Assets | NT$106.15 Billion |
| Market Capitalization | $1.35 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Lotus Pharmaceutical Co Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lotus Pharmaceutical Co Ltd's assets grew by 164.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lotus Pharmaceutical Co Ltd (2009–2025)
The table below shows the annual total assets of Lotus Pharmaceutical Co Ltd from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$106.15 Billion ≈ $3.34 Billion |
+164.72% |
| 2024-12-31 | NT$40.10 Billion ≈ $1.26 Billion |
+21.55% |
| 2023-12-31 | NT$32.99 Billion ≈ $1.04 Billion |
+11.74% |
| 2022-12-31 | NT$29.53 Billion ≈ $930.23 Million |
+39.13% |
| 2021-12-31 | NT$21.22 Billion ≈ $668.61 Million |
+7.43% |
| 2020-12-31 | NT$19.75 Billion ≈ $622.34 Million |
+10.24% |
| 2019-12-31 | NT$17.92 Billion ≈ $564.51 Million |
+20.63% |
| 2018-12-31 | NT$14.85 Billion ≈ $467.97 Million |
-5.14% |
| 2017-12-31 | NT$15.66 Billion ≈ $493.35 Million |
+2.72% |
| 2016-12-31 | NT$15.24 Billion ≈ $480.27 Million |
-1.66% |
| 2015-12-31 | NT$15.50 Billion ≈ $488.40 Million |
-4.72% |
| 2014-12-31 | NT$16.27 Billion ≈ $512.60 Million |
+713.28% |
| 2013-12-31 | NT$2.00 Billion ≈ $63.03 Million |
+84.37% |
| 2012-12-31 | NT$1.09 Billion ≈ $34.19 Million |
-3.19% |
| 2011-12-31 | NT$1.12 Billion ≈ $35.31 Million |
-1.75% |
| 2010-12-31 | NT$1.14 Billion ≈ $35.94 Million |
+61.36% |
| 2009-12-31 | NT$706.92 Million ≈ $22.27 Million |
-- |
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more